Neurogenics logo
Science

Upstream biology, not downstream symptoms.

Our scientific programme investigates the mechanisms shared across the diseases of ageing, and how characterised bioactive flavanols interact with them. Earlier research has largely relied on cocoa solids or synthetic flavanols recovered by chemical extraction to fortify them. Our patented process is designed to retain and characterise flavanols and (−)-epicatechin, alongside the dense nutrients naturally present in the input material. The materials used in previous studies differ from the composite materials that we have developed and patented.

Platform Position

A flavanol technology platform, not a product.

Neurogenics is developing an evolving technology platform at the convergence of food, medicines, pharmaceuticals, nutraceuticals and botanicals.

Neurogenics

Flavanol
Technology
Platform

  • FOOD
  • MEDICINES
  • PHARMACEUTICALS
  • NUTRACEUTICALS
  • BOTANICALS

The diagram describes the strategic and scientific space in which the platform is being developed. It is not a statement of regulatory status in any category.

Shared Mechanism

How the biology connects.

  1. 01

    Ageing

    Accumulating cellular and metabolic burden.

  2. 02

    Inflammation

    Persistent low grade inflammatory signalling.

  3. 03

    Vascular Dysfunction

    Declining endothelial performance.

  4. 04

    Cardiometabolic Disease

    Hypertension, diabetes, cardiovascular disease.

  5. 05

    Reduced Healthspan

    Loss of healthy, independent years.

Scientific Position

Evidence first. Claims only when earned.

Neurogenics makes no clinical claims as yet. We are preparing for independent clinical validation and seeking the funding required to undertake that programme. We are an industrial biotechnology company building the analytical and evidentiary foundation required for credible health applications at every level of medicinal product development.

Published literature describes relationships between cocoa flavanols and vascular function. EFSA has authorised a maintenance-of-vasodilation claim at 200 mg of cocoa flavanols per day, and mechanistic work attributes the effect to (−)-epicatechin and nitric-oxide signalling.1,3 The largest randomised trial to date, COSMOS, did not meet its primary cardiovascular endpoint, though a pre-specified secondary analysis of cardiovascular death favoured supplementation.2 Our programme tests whether a standardised, retention-engineered flavanol fraction can be reproducibly characterised and independently evaluated against that mixed evidence base.

Results, protocols and citations will be published here as the programme progresses.

Workstreams

Current scientific programme.

  • Analytical characterisation

    Composition, stability and standardisation of flavanol fractions across processing conditions.

    COMPLETED

  • Mechanistic review

    Structured review of published mechanisms linking flavanols to vascular and metabolic biology.

    COMPLETED

  • Clinical Validation Programme

    Independent human study design and preparation for clinical validation.

    IN DEVELOPMENT
Development pipeline

From analytical validation to clinical evidence.

Neurogenics is progressing through a staged evidence-development pathway. Each stage is intended to build the analytical, clinical and manufacturing evidence required before the platform advances to the next.

  1. 01COMPLETED

    Analytical validation

    Characterisation and analysis of the flavanol platform against the compositional requirements relevant to the established cocoa-flavanol evidence base.

  2. 02CURRENT

    Clinical programme design

    Development of the independent human study programme required to evaluate the Neurogenics platform clinically.

  3. 03CURRENT

    Clinical trial funding

    Securing the funding required to undertake independent clinical validation.

  4. 04PLANNED

    Independent clinical validation

    Human clinical evaluation of the characterised Neurogenics material against defined endpoints.

  5. 05FUTURE

    Manufacturing scale-up

    Scale-up of the protected processing platform following successful clinical validation.

  6. 06FUTURE

    Partnerships & licensing

    Commercial development through manufacturing, ingredient and licensing partnerships, subject to the evidence generated.

Pipeline stages describe Neurogenics’ development plan and are not regulatory approvals or guarantees of clinical outcome. Future stages are dependent on funding, study results and applicable regulatory requirements.

Why does this matter?

Cardiometabolic disease and population ageing are the dominant pressures on health systems worldwide. Shared upstream biology offers leverage across several conditions at once.

Why now?

Analytical, mechanistic and regulatory understanding of bioactives is now sufficient to support rigorous evaluation.

Why Neurogenics?

We are building the evidence infrastructure: disease data, analytical characterisation and independent study design, alongside regulatory framework mapping.

References

  1. 01EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of a health claim related to cocoa flavanols and maintenance of normal endothelium-dependent vasodilation. EFSA Journal 2012;10(7):2809. Source
  2. 02Sesso HD, Manson JE, Aragaki AK, et al.. Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COSMOS randomized clinical trial. Am J Clin Nutr 2022;115(6):1490–1500. Source
  3. 03Schroeter H, Heiss C, Balzer J, et al.. (−)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. PNAS 2006;103(4):1024–1029. Source
  4. 04GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors, 1990–2021. The Lancet 2024;403(10440):2162–2203. Source
  5. 05World Health Organization. Global report on hypertension: the race against a silent killer. WHO, 2023. Source